Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported its financial results for the third quarter ending September 30, 2024. Teva’s President and CEO, Richard Francis, commented, “We’ve achieved…
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced the design of a pivotal Phase 3 clinical trial for ION582, an investigational treatment for Angelman syndrome (AS), following successful alignment with the…
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-driven cancers, reported its third-quarter financial results for the period ending September 30, 2024, and…
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company developing transformative gene-based medicines for serious diseases, has released its financial results for Q3 ending September 30, 2024. “We are making strong progress…
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company specializing in treatments for central nervous system (CNS) disorders, has announced positive results from Study 304, which evaluated the efficacy and safety…
BridgeBio Pharma, Inc. (Nasdaq: BBIO), an innovative biopharmaceutical company focused on treating genetic diseases, has announced the publication of a case study, “Applications of Portfolio Theory to Accelerating Biomedical Innovation,”…
Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) have announced a $350 million synthetic royalty funding agreement, tied to the U.S. net sales of Niktimvo (axatilimab-csfr). “We are…
BioNTech SE (Nasdaq: BNTX) has announced its financial results for the third quarter and the first nine months of 2024, alongside updates on its corporate initiatives. During this period, the…
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, has announced the appointment of Alan Bash as the President of CARVYKTI®. In this newly established position, Mr. Bash…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) showcased findings from the long-term KINECT®-4 study, revealing that nearly 60% of participants achieved remission from tardive dyskinesia after 48 weeks of treatment with once-daily…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the launch of a new disease awareness campaign titled “We’ll Get There Soon” on FCS Awareness Day. The initiative aims to raise awareness…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) recently presented data from over 300 patients with tardive dyskinesia treated with INGREZZA® (valbenazine) capsules, revealing significant improvements in functional, social, emotional, and health-related quality…